Safety of plasma-derived blood products transfusions harvested from anti-SARS-CoV-2 positive and negative donors

   Introduction. Testing for antibodies to the causative agent COVID-19 is not mandatory for donor blood or its components. It is unknown whether transfusion of plasma-containing blood components from seropositive donors is a safe procedure especially for immunocompromised hematological patients.

   Aim. To assess the frequency of adverse reactions and complications in hematological patients after transfusions of plasma-derived blood products harvested from anti-SARS-CoV-2 positive and negative donors.

   Material and Methods. 9152 transfusions of components harvested from anti-SARS-CoV-2 positive and negative donors were carried out from April 29, 2020 to January 21, 2022 at the NMRC for Hematology. Post-transfusion reactions and complications were analyzed in 576 hematological patients. 2059 plasma units, 327 cryosupernatant plasma units and 6766 cryoprecipitate doses were assessed. The occurrence of adverse reactions (hyperthermia) and complications within two hours after transfusion were evaluated.

   Results. Among 9152 blood units, anti-SARS-CoV-2 were detected in 2660 (29 %) cases and 6492 (71 %) were antibodies free. The analysis of adverse reactions and complications showed no significant differences in the incidence of adverse reactions in recipients after anti-SARS-CoV-2 positive and negative blood unit transfusions.

   Conclusion. There were no significant differences in the number of post-transfusion reactions when using donor blood components (fresh frozen plasma, cryosupernatant plasma, cryoprecipitate) obtained from donors in whose blood antibodies to SARS-CoV-2 were detected or not detected. Plasma-derived blood products from seropositive donors with a high degree of probability can be used to correct the plasma hemostasis path in hematological patients along with components prepared from seronegative donors.

1. Vyalykh N.A. Russian public’s social trust to healthcare system: new meanings and theoretical foundations during the COVID-19 pandemic. Vestnik Nizhegoro-dskogo universiteta im. NI Lobachevskogo. Seriya: Sotsial’n·yye nauki. 2022; 2(66): 104–11 (In Russian).

2. Yang, P., Wang, X. COVID-19: a new challenge for human beings. Cell Mol Immunol. 2020; 17: 555–7. DOI: 10.1038/s41423-020-0407-x.

3. Bhagat S., Yadav N., Shah J., et al. Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. Expert Rev Anti-Infect Ther. 2022; 20(10): 1275–98. DOI: 10.1080/14787210.2021.1835469.

4. Garafutdinov R.R., Mavzyutov A.R., Nikonorov Yu.M. Betacoronavirus SARS-CoV-2, its genome, diversity of genotypes and molecular biological measures to combat it. Biomika. 2020; 12(2): 242–71 (In Russian). DOI: 10.31301/2221-6197.bmcs.2020-15.

5. Kuznetsov S.I., Kudinova E.V., Zhiburt, E.B. Blood banking during COVID-19. Menedzher zdravookhraneniya. 2020; 5: 40–3 (In Russian).

6. Eykhler O.V., Chechetkin A.V., Adzhigitova Y.V., et al. Characteristics of reactions and complications after blood transfusion in medical organizations of the Russian Federation in 2019. Transfuziologiya. 2020; 21(4): 304–12 (In Russian).

7. Baklaushev V.P., Kulemzin S.V., Gorchakov A.A., et al. COVID-19. Ethology, pathogenesis, diagnostics and treatment Klinicheskaya praktika. 2020; 11(1): 7–20 (In Russian). DOI: 10.17816/clinpract26339.

8. Kogan E.A., Berezovskiy Yu.S., Protsenko D.D., et al. Pathological anatomy of SARS-CoV-2 infection. Sudebnaya meditsina. 2020; 6(2): 8–30 (In Russian).

9. Order of the Ministry of Health of Russia dated October 28, 2020 No. 1166n “On approval of the procedure for donors to undergo a medical examination and a list of medical contraindications (temporary and permanent) for donating blood and (or) its components and the timing of the withdrawal to which a person is subject in the presence of temporary medical indications from donation blood and (or) its components” (In Russian). URL: https://www.garant.ru/products/ipo/prime/doc/74861670/

10. Mandate of the Government of the Russian Federation of June 22, 2019 No. 797 “On approval of the Rules for the procurement, storage, transportation and clinical use of donor blood and its components and on the invalidation of certain acts of the Government of the Russian Federation” (In Russian). URL: https://base.garant.ru/72284110/

11. Fernández-Lázaro D., Ortega C. D., Sánchez-Serrano N. Et al. Convalescent Plasma Therapy. Therapeutic Formulations of Repurposed Drugs in 20th Century, Epidemics against COVID-19: A Systematic Review. Pharmaceutics. 2022; 14(5): 1020. DOI: 10.3390/pharmaceutics14051020.

12. Golosova T.V., Anikina T.A., Zakhar’yevskaya N.S. Anti-staphylococcal gamma-globulin in the comprehensive therapy of purulent-infl ammatory staphylococcal diseases. Klinicheskaya meditsina. 1974; 52(6): 115–7 (In Russian).

13. Bajpai M., Maheshwari A., Dogra V., et al. Effi cacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial). BMJ open. 2022; 12(4): e055189. DOI: 10.1136/bmjopen-2021-055189.

14. FDA Convalescent Plasma EUA Letter of Authorization 12282021. URL: https://www.fda.gov/media/141477/download